21st Annual Superbugs & Superdrugs Conference

SMi Group18 - 19 March 2019, London, UK.
As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections.

SMi's highly anticipated Superbugs & Superdrugs conference is set to return to London, UK for its 21st year running, on the 18th & 19th March 2019. This year's event aims to provide valuable insights and key updates on the latest developments within the scientific communities, as well as the processes and strategies pharmaceuticals use to develop novel therapeutics that utilise alternative mechanisms to treat multi-drug resistant infections.

The two-day conference will also host a diverse gathering of policy makers and economists, in addition to big pharmas and biotechs, who will discuss incentives, partnerships, regulations and new policies. Industry experts and scientific pioneers are set to present on their research advances and clinical data, as well as alternatives to antibiotics, such as monoclonal antibodies and antimicrobial peptides.

2019 Highlights

  • Analyse the current status of antimicrobial resistance with industry-led insight into current strategies to tackle AMR
  • Hear about novel immune-therapeutics to target Gram-negative bacterial infections
  • Learn about strategies to combat β-lactamases
  • Evaluate the development of precision antibiotics: Agents designed to meet the demands of stewardship
  • Explore the role of plasmids in the evolution of antimicrobial resistance

Join us in London next year to explore the challenges and solutions to the growing threat of antibiotic resistance, as well as take part in interactive roundtable discussions with leading organisations. Attendees will also have the exclusive opportunity of networking with an unrivalled gathering of senior experts from Chemical Biology Ventures, University of Oxford, MedImmune, HPRA, GARDP, DNDi, Bioharmony Therapeutics, and many more.

For further information and to register, please visit:
http://www.superbugssuperdrugs.com/wpnwl

Early Bird Discounts

  • Book by November 30th and save £400
  • Book by December 14th and save £200
  • Book by January 31st and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Lilly and Lycia Therapeutics enter into strategic …

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, devel...

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...